InvestorsHub Logo
Followers 6
Posts 881
Boards Moderated 0
Alias Born 09/28/2012

Re: Fred Kadiddlehopper post# 6738

Monday, 09/20/2021 6:39:54 PM

Monday, September 20, 2021 6:39:54 PM

Post# of 8791
The quote below is from a Morningstar analyst report on Genmab. $11.3B is the highest sales estimate I've seen for Darzalex but in any case you can see that even just for Darzalex any "step down" in 2024 and 2027 from "mid-single digits" would be significant, so it's not surprising that analysts keep asking about it.

"We think Darzalex will continue to be a widely used treatment for multiple myeloma due to its notable efficacy and safety profile. By 2030, we model over $11.3 billion in Darzalex sales, which corresponds to about DKK 13 billion in royalties to Genmab."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News